Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
South Korea Inflation Rises to 2.3% in December, Matching Market Expectations 
Pop Mart Shares Surge in Hong Kong After First Buyback in Nearly Two Years 
Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion 
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading 
Wall Street Ends Mixed as Tech and Financial Stocks Weigh on Markets Amid Thin Holiday Trading 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Samsung Electronics’s executive chairman, Lee Jae Yong, has been holding meetings with leaders of the leading biopharmaceutical and biotechnology companies to forge joint ventures or enter into partnership deals.
The Samsung Electronics chief reportedly met up with global executives of some leading brands in the biotech and biopharma industry, including Johnson & Johnson’s chief executive officer, Joaquin Duato; Biogen’s chief, Christopher Viehbacher; Bristol Myers Squibb’s CEO, Giovanni Caforio; Kevin Ali, Organon’s CEO; and Noubar Afeyan of Flagship Pioneering.
Lee held meetings with them during his recent trip to the United States. Korea Joongang Daily reported that the Samsung leader has a goal of securing partnership agreements with them as he is seeing the biopharma and biotech fields as the company’s new growth drivers.
The Samsung chairman also commented during his trip, "The starting point is not important, but bold and persistent challenges set victory apart from defeat. Let us continue the success story of chips with bio."
In any case, Lee Jae Yong is trying to get contracts for the company’s CMDO arm, Samsung Biologics, which is currently the largest contract manufacturing and development organization in the world based on production capacity.
While it is a latecomer in this market, Samsung Biologics is doing fairly well since it was first established in 2011. Samsung Electronics owns 31.22% of shares in its affiliate CMDO firm.
"The bio-industry is a field with high barriers to entry, requiring not only production technology and R&D capabilities but also trust and reputation building for long-term collaboration,” The Korea Times quoted Samsung as saying in a statement regarding the chairman's move to seek collaborations with US bio companies. “Lee's wide global network is expected to serve as a lever for Samsung's bio business to expand collaboration with big pharmaceutical companies and create future growth opportunities."
